Voyager Therapeutics (VYGR) Non Operating Interest Expenses (2014 - 2016)

Voyager Therapeutics has disclosed Non Operating Interest Expenses across 3 years of filings, most recently posting -$283000.0 for Q2 2016.

• In Q2 2016, Non Operating Interest Expenses fell 293.06% year-over-year to -$283000.0; the TTM figure through Jun 2016 stood at -$664000.0 (down 106.5% YoY), while the FY2015 annual figure was $9.8 million, up 400.0% from the prior year.
• Non Operating Interest Expenses came in at -$283000.0 for Q2 2016 at Voyager Therapeutics, down from -$279000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $9.7 million in Q1 2015 to a low of -$283000.0 in Q2 2016.
• Average Non Operating Interest Expenses over 3 years is $1.4 million, with a median of -$72000.0 recorded in 2015.
• The largest YoY upside for Non Operating Interest Expenses was 102.86% in 2016 against a maximum downside of 293.06% in 2016.
• Over 3 years, Non Operating Interest Expenses stood at $194000.0 in 2014, then sank by 152.58% to -$102000.0 in 2015, then plunged by 177.45% to -$283000.0 in 2016.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were -$283000.0 in Q2 2016, -$279000.0 in Q1 2016, and -$102000.0 in Q3 2015.